Open Government Portal

The purpose of this Notice of Amendment is to notify about the addition of casirivimab and imdevimab to the Prescription Drug List (PDL) for human and veterinary use.

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for diclofenac on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.

The purpose of this Notice of Amendment is to notify that Health Canada will switch certain uses of Esomeprazole to nonprescription status for human use by modifying the Human Prescription Drug List (PDL). The Veterinary List will remain unchanged.

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for omeprazole on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.

The purpose of this Notice of Amendment is to notify that Health Canada will revise the listing for Adrenocortical hormones on the Prescription Drug List (PDL) to exempt certain uses of Fluticasone propionate.

The purpose of this Notice of Amendment is to notify that Health Canada has amended 14 antimicrobial active ingredients or their salts or derivatives from non-prescription to prescription on the Veterinary Prescription Drug List (PDL). These amendments include adding antimicrobial classes, listing certain antimicrobials as derivatives rather than as antibiotic classes, and deleting qualifiers that are no longer necessary.

The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will revise the listing for hydrocortisone on the Prescription Drug List (PDL). Only the Human part of the PDL is to be revised; the listing for Veterinary use will remain unchanged.

The purpose of this Notice of Amendment is to notify that Health Canada will switch injectable Hyoscine butylbromide to prescription status from ethical status for human use by adding it to the Human Prescription Drug List (PDL). Injectable Hyoscine butylbromide is already listed on the Veterinary Prescription Drug List.

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for minoxidil on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.

The purpose of this Notice of Amendment is to notify that as a result of consultation Health Canada has revised the listing for naloxone on the Prescription Drug List (PDL).